Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
Harvard Business School
Mallinckrodt
AstraZeneca
Medtronic
McKesson

Last Updated: January 22, 2020

DrugPatentWatch Database Preview

Claims for Patent: 9,526,644

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: 9,526,644
Title:Optimized drug-eluting stent assembly methods
Abstract: Methods of preparing and using a stent assembly that includes a stent jacket formed from an expansible mesh structure having apertures and that includes a fiber having a diameter of about 7 micrometers and about 40 micrometers, and an expansible stent operatively associated with the stent jacket. The method further comprises administering to the subject an active pharmaceutical ingredient (API) eluted from the stent assembly.
Inventor(s): Bar; Eli (Moshav, IL), Holzer; Asher (Raanana, IL), Paz; Ofir (Rishon Lezion, IL)
Assignee: InspireMD, Ltd. (Tel Aviv, IL)
Application Number:14/851,882
Patent Claims:1. A method of stenting which comprises implanting in a body lumen of a subject a stent assembly that comprises: a stent configured to be positioned in the body lumen; and a knitted stent jacket comprising an expansible mesh structure disposed over a circumference of the stent and along an entire length thereof, the mesh structure being formed from a single fiber and having a coverage area of about 9% to less than 25% relative to the coverage area of a plurality of apertures therein, the apertures having approximate aperture diameters greater than 20 micrometers up to a minimum center dimension of 234 micrometers and the knitted stent jacket being coaxially associated with the stent, wherein the stent assembly elutes an amount of an active pharmaceutical agent that is present therein, and wherein the fiber has a diameter of approximately 7 micrometers to 40 micrometers.

2. The method of claim 1, which comprises eluting the active pharmaceutical agent from the stent.

3. The method of claim 1, which comprises eluting the active pharmaceutical agent from a coating disposed over a portion of the stent.

4. The method of claim 1, which comprises releasing the active pharmaceutical agent over time according to a predetermined treatment schedule.

5. The method of claim 4, wherein the treatment schedule is selected to cover a period of 8 hours to a plurality of months.

6. The method of claim 1, which comprises eluting the active pharmaceutical agent from the knitted stent jacket.

7. The method of claim 1, which comprises eluting the active pharmaceutical agent from a coating on the expansible mesh structure.

8. The method of claim 1, wherein the coaxial association comprises sewing, adhering, gluing, folding, or suturing the knitted stent jacket to the stent.

9. The method of claim 8, wherein the coaxial association comprises suturing the knitted stent jacket to the stent.

10. The method of claim 1, which further comprises attaching a proximal portion of the knitted stent jacket to a proximal portion of the stent.

11. The method of claim 10, which further comprises attaching a distal portion of the stent jacket to a distal portion of the stent.

12. The method of claim 1, wherein the amount of active pharmaceutical agent eluted comprises a therapeutically effective amount to treat a disorder in a carotid or coronary artery, or a cerebral aneurism.

13. The method of claim 1, wherein the active pharmaceutical agent is eluted from any combination of the stent, a coating on the stent, the knitted stent jacket, or a coating on the knitted stent jacket.

14. The method of claim 1, which comprises forming the mesh structure from a polymer component comprising one or more poly lactic-co-polyglycolic ("PLGA"), polycaprolactone ("PCL"), polygluconate, polylactic acid-polyethylene oxide, poly(hydroxybutyrate), polyanhydride, poly-phosphoester, poly(amino acids), poly-L-lactide, poly-D-lactide, polyglycolide, or poly(alpha-hydroxy acid) co-polymer(s), polyethylene terephthalate, or any combination thereof.

15. The method of claim 14, wherein the mesh structure is selected to comprise a single polymer fiber.

16. The method of claim 15, wherein the polymer is elastic, biocompatible, and hemocompatible.

17. The method of claim 1, wherein the expansible mesh structure is selected to comprise a retracted state and a deployed state, and further selected to define apertures having a minimum center dimension of 150 micrometers to 200 micrometers in the deployed state.

18. The method of claim 1, wherein the expansible mesh structure is selected to comprise a retracted state and a deployed state, and further selected to define apertures having a minimum center dimension of 150 micrometers to 180 micrometers in the deployed state.

19. The method of claim 1, wherein the active pharmaceutical agent is selected to comprise zolimus, zotarolimus, sirolimus, taxol/paclitaxel, or a combination thereof.

20. The method of claim 1, wherein the active pharmaceutical agent is selected to comprise an anti-proliferative agent, an antithrombotic agent, an anticoagulant, an antioxidant, a growth factor inhibitor, a collagen inhibitor, a liposome, a steroid or corticosteroid, a statin, endothelial cell seeds, a hydrogel containing endothelial cells, or a combination thereof.

21. The method of claim 20, wherein the anti-proliferative agent is present and comprises sirolimus, zolimus or zotarolimus, a taxane, tacrolimus, everolimus, vincritine, viblastine, a HMG-CoA reductase inhibitor, doxorubicin, colchicine, actinomycin D, mitomycin C, cycloporine, mycophenolic acid, triazolopyrimidine, or a combination thereof; wherein the antithrombotic agent is present and comprises heparin, a heparin-like dextran derivative, acid citrate dextrose, coumadin, warfarin, streptokinase, anistreplase, tissue plasminogen activator (tPA), urokinase, abciximab, or a combination thereof wherein the growth factor inhibitor is present and comprises tranilast, angiopeptin, or a combination thereof; wherein the steroid or corticosteroid is present and comprises cortisone, prednisolone, or both; wherein the statin is present and comprises simvastatin, lovastatin, or a combination thereof; or any combination of the foregoing.

22. The method of claim 1, wherein the stent assembly is selected to comprise 1 microgram to 200 micrograms of each pharmaceutical agent.

23. The method of claim 1, wherein the mesh of the knitted stent jacket is selected to comprise 1 microgram to 200 micrograms of each pharmaceutical agent.

24. The method of claim 1, wherein the active pharmaceutical agent is selected to comprise a `limus drug at a concentration of 10 .mu.g/mm.sup.2 to 80 .mu.g/mm.sup.2.

25. The method of claim 1, wherein the active pharmaceutical agent is selected to comprise a `limus drug at a concentration of 80 .mu.g/mm.sup.2 to 140 .mu.g/mm.sup.2.

26. The method of claim 2, wherein the stent is selected to comprise a metal alloy coated with a biodegradable polymer, biostable polymer, bioresorbable polymer, or a combination thereof.

27. The method of claim 1, wherein the stent is selected to comprise a biodegradable material.

28. The method of claim 27, wherein the biodegradable material is selected to comprise a polymer.

29. The method of claim 27, wherein the biodegradable material is selected to comprise a metal alloy.

30. A method of preparing a stent assembly which comprises: providing a stent configured to be positioned in the body lumen; and coaxially disposing a knitted stent jacket comprising an expansible mesh structure over a circumference of the stent and along a length thereof, the mesh structure being formed from a single fiber and having a coverage area of about 9% to less than 25% relative to the coverage area of a plurality of apertures therein, the apertures having approximate aperture diameters greater than 20 micrometers up to a minimum center dimension of 234 micrometers, wherein the stent assembly elutes an amount of an active pharmaceutical agent that is present therein, and wherein the fiber has a diameter of approximately 7 micrometers to 40 micrometers.

Details for Patent 9,526,644

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Centocor Inc REOPRO abciximab INJECTABLE; INJECTION 103575 001 1994-12-22   Start Trial InspireMD, Ltd. (Tel Aviv, IL) 2026-11-22 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Baxter
Mallinckrodt
McKesson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.